(RTTNews) - Radiopharm Theranostics Limited (RADX), on Monday announced promising new data from the European Molecular Imaging Meeting or EMIM 2025, showcasing the potential of 68Ga-RAD202 for imaging ...
The testing demonstrated an impressive six-hour stability of TLX591-CDx, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron ...
Bicycle radionuclide conjugates (BRCs) have been developed as a unique radiotheranostic modality for imaging and targeting of proteins overexpressed by tumors, and they possess favorable drug-like ...
BURNABY, British Columbia & INDIANAPOLIS--(BUSINESS WIRE)--ARTMS Inc. (‘ARTMS’) and Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) are pleased to announce they have successfully produced Telix’s ...
Burnaby, British Columbia, Canada & Indianapolis, United States: ARTMS Inc. (‘ARTMS’) and Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) are pleased to announce they have successfully produced ...
ARTMS Inc. (‘ARTMS’) and Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) are pleased to announce they have successfully produced Telix’s prostate cancer imaging product, TLX591-CDx (Kit for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results